Fears of heightened scrutiny by the FDA will be calmed by a look at historic rates of complete response letters.
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.
Inflarx looks to its lead asset in a rare skin disease, while smoking cessation success could trigger partnering talks for Achieve Life Sciences.
December will be a big month for Achillion's complement inhibitor and Aquestive's ALS hopes.
Loosening of clinical requirements has encouraged more projects into the IgA nephropathy pipeline, with a steroid–based approach from Sweden’s Calliditas looking…